Avexxin has several molecules in the pipeline at different developmental stages, targeting the group IVA cPLA2 enzyme. The newest molecules were added to the portfolio in 2015.
All of Avexxin’s small molecules are nanomolar potent drug candidates targeting chronic inflammatory disorders and cancers with high unmet need. The individual compounds represent a series of international drug discovery efforts conducted in collaboration with key leaders in the field
With our lead compound – AVX001 – we are developing a novel therapy for the treatment of psoriasis and other skin conditions. The mechanism based, rationally designed, lead compound is a potent inhibitor of TNFa induced inflammation in keratinocytes, and a potent candidate for a powerful anti-psoriatic drug.